Condition: Dravet Syndrome · Sponsor: Stoke Therapeutics, Inc
The purpose of the study is to evaluate the efficacy, safety, and tolerability of zorevunersen in Patients with Dravet syndrome.
This description comes directly from the study's public registry record.
Emperor Information Center · 1-781-430-8200 · info@emperorstudy.com
Always discuss trial participation with your own doctor first.
| Phoenix Children's Hospital | Phoenix, Arizona, United States | Active Not Recruiting |
| Arkansas Children's Hospital | Little Rock, Arkansas, United States | Active Not Recruiting |
| Cedars Sinai Medical Center | Los Angeles, California, United States | Active Not Recruiting |
| Children's Hospital of Orange County | Orange, California, United States | Active Not Recruiting |
| USCF Medical Center | San Francisco, California, United States | Active Not Recruiting |
| Children's Hospital Colorado | Aurora, Colorado, United States | Active Not Recruiting |
| Children's National Medical Center | Washington D.C., District of Columbia, United States | Active Not Recruiting |
| Nemours Children's Health | Jacksonville, Florida, United States | Active Not Recruiting |
| Nicklaus Children's Hospital | Miami, Florida, United States | Active Not Recruiting |
| Advent Health Neuroscience Research Institute | Orlando, Florida, United States | Active Not Recruiting |
| Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago, Illinois, United States | Active Not Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Active Not Recruiting |
+ 46 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06872125